The immune system exists in harmony and also with the potential for dynamic control in healthy individuals. Our healthy body needs to sense the presence of microbes and react through both innate and adaptive immunity to eliminate infection. How our immune system senses the initiation, progression, and termination of the inflammatory process is critical for maintaining immune homeostasis. Thanks to the elegant experimental progress in using conditional knockout animal models, we have, over the past decade, gained a deep understanding of the contributions of thymus-derived CD4+CD25+Foxp3+ natural regulatory T cells (Tregs) to this process.
Although there have been many advances in our understanding, it remains unclear how the adaptive immune system, including natural and induced Foxp3+ Tregs, plays a central role in suppressing immune responses, sensing inflammation, and ensuring appropriately timed and localized immune responses, especially in humans.1,2 It is still actively debated whether Treg plasticity exists and/or how it is dynamically controlled both in healthy and inflammation states. On the one hand, it has been convincingly demonstrated that the Foxp3 gene locus is consistently demethylated and actively transcribed in natural Treg cells.3,4,5 On the other hand, the Foxp3 protein is regulated at the posttranslational level by acetylation, phosphorylation, and ubiquitination, which detemine its DNA binding, protein stability, and degradation under inflammation.6,7,8,9,10 Understanding functional plasticity and stability could provide new insights in promoting Treg-based clinical therapies for autoimmune disease, organ transplantation, and cancer.11
In this issue, we have assembled a series of up-to-date reviews on the functional plasticity of Tregs to address and discuss how Tregs may sense the initiation and progression of inflammation in different physiological microenvironments. In an inflammatory microenvironment, a small subpopulation of Treg cells may lose the expression and/or function of the Treg cell lineage master regulator Foxp3 and function as inflammatory cytokine-producing pathogenic effector T cells (Teff cells), which were initially identified by and have been reviewed by Xuyu Zhou et al.12,13 The induction and function of recently identified inflammatory Teff cells, called Th17 cells, are tightly controlled by differential nuclear receptors, as reviewed by Benjamin V. Park and Fan Pan.14 Moreover, Treg cells may function locally and adapt to the tissue microenvironment in lymphoid and non-lymphoid tissues, including skin, muscle, adipocytes, and tumors, as reviewed by Zhou et al.15 Over a decade ago, it was discovered that Foxp3+ Treg cells could also be differentiated and induced from naive T cells in vitro and in vivo under TCR activation and costimulation by anti-inflammatory cytokines such as TGF-β. Liu et al. summarize recent progress in understanding the induction and function of induced Treg cells and their functional stability as modified by all-trans retinoic acid.16 Zhiyuan Li et al. provide an update on the molecular mechanism by which the Foxp3 protein is dynamically regulated at the posttranslational level by inflammatory stimuli, as well as functional applications for clinical therapies.17 In addition to Foxp3-expressing Treg cells, IL-10-producing but Foxp3-negative T regulatory cells, called Type 1 regulatory T (Tr1) cells, may also play a critical role in controlling immune homeostasis. Hanyu Zeng et al. summarize the induction and functional characterization of this important subset of Treg cells and their potential clinical applications.18 More recently, it has been found that during the terminal and recovery phases of inflammation, inflammatory Th17 cells can transdifferentiate into immune suppressive Tr1 cells.19 Future studies on the plasticity and transdifferentiation of Treg and Teff cells could provide therapeutic applications for treating human inflammatory diseases.
References
Zheng SG, Gray JD, Ohtsuka K, Yamagiwa S, Horwitz DA . Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25− precursors. J Immunol 2002; 169: 4183–4189.
Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N et al. Conversion of peripheral CD4+CD25− naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875–1886.
Rubtsov YP, Niec RE, Josefowicz S, Li L, Darce J, Mathis D et al. Stability of the regulatory T cell lineage in vivo. Science 2010; 329: 1667–1671.
Feng Y, Arvey A, Chinen T, van der Veeken J, Gasteiger G, Rudensky AY et al. Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus. Cell 2014; 158: 749–763.
Josefowicz SZ, Niec RE, Kim HY, Treuting P, Chinen T, Zheng Y et al. Extrathymically generated regulatory T cells control mucosal TH2 inflammation. Nature 2012; 482: 395–399.
Li B, Samanta A, Song X, Iacono KT, Bembas K, Tao R et al. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc Natl Acad Sci USA 2007; 104: 4571–4576.
Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 2011; 146: 772–784.
Laurence A, Belkaid Y, O’Shea JJ . A degrading view of regulatory T cells. Immunity 2013; 39: 201–203.
Chen Z, Barbi J, Bu S, Yang HY, Li Z, Gao Y et al. The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3. Immunity 2013; 39: 272–285.
van Loosdregt J, Fleskens V, Fu J, Brenkman AB, Bekker CP, Pals CE et al. Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity 2013; 39: 259–271.
Sakaguchi S, Vignali DA, Rudensky AY, Niec RE, Waldmann H . The plasticity and stability of regulatory T cells. Nat Rev Immunol 2013; 13: 461–467.
Gagliani N, Vesely MC, Iseppon A, Brockmann L, Xu H, Palm NW et al. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature 2015; 523: 221–225.
Guo J, Zhou X . Regulatory T cells turn pathogenic. Cell Mol Immunol 2015. doi :10.1038/cmi.2015.12.
Park BV, Pan F . The role of nuclear receptors in regulation of Th17/Treg biology and its implications for diseases. Cell Mol Immunol 2015. doi :10.1038/cmi.2015.021.
Zhou X, Tang J, Cao H, Fan H, Li B . Tissue resident regulatory T cells: novel therapeutic targets for human disease. Cell Mol Immunol 2015. doi :10.1038/cmi.2015.23.
Liu ZM, Wang KP, Ma J, Zheng SG . The role of all-trans retinoic acid in the biology of Foxp3 regulatory T cells. Cell Mol Immunol 2015. doi :10.1038/cmi.2014.133.
Li Z, Li D, Tsun A, Li B . FOXP3 regulatory T cells and their functional regulation. Cell Mol Immunol 2015. doi :10.1038/cmi.2015.10.
Zeng H, Zhang R, Jin B, Chen L . Type 1 regulatory T cells: a new mechanism of peripheral immune tolerance. Cell Mol Immunol 2015. doi :10.1038/cmi.2015.44.
Gagliani N, Vesely M.C, Iseppon A, Brockmann L, Xu H, Palm N.W, de Zoete M.R, Licona-Limon P, Paiva R.S, Ching T et al. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature 2015; 523: 221–225.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Li, B., Zheng, S. How regulatory T cells sense and adapt to inflammation. Cell Mol Immunol 12, 519–520 (2015). https://doi.org/10.1038/cmi.2015.65
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cmi.2015.65
This article is cited by
-
A unified model of the biology of peripartum depression
Translational Psychiatry (2023)
-
Anti-allergic rhinitis activity of α-lipoic acid via balancing Th17/Treg expression and enhancing Nrf2/HO-1 pathway signaling
Scientific Reports (2020)